Journal article
The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
American journal of clinical pathology, Vol.135(1), pp.54-61
01/01/2011
DOI: 10.1309/AJCPJX4BJV9NLQHY
PMID: 21173124
Abstract
The cellular composition of the tumor microenvironment may affect survival in diffuse large B-cell lymphoma (DLBCL). We performed immunostains for 2 stromal cell markers, CD68 and SPARC (secreted protein, acidic and rich in cysteine), in 262 patients with DLBCL treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapies. Patients with any SPARC+ cells in the microenvironment had a significantly longer overall survival, and patients with high SPARC positivity in the microenvironment also had a significantly longer event free survival. Survival differences were mainly due to the prognostic effect of SPARC+ cells in activated B-cell (ABC)-type DLBCL, with no effect found in the germinal center B-cell type DLBCL. Of clinical features examined, only the number of extranodal sites was significantly associated with SPARC expression. Multivariate analysis revealed that SPARC expression predicted patient survival independent of the International Prognostic Index or tumor cell of origin. SPARC expression in the microenvironment of DLBCL can be used for prognostic purposes, determining a subgroup of patients with ABC DLBCL who have significantly longer survival. More aggressive chemotherapy protocols should be considered for patients with ABC DLBCL without SPARC+ stromal cells. CD68 expression by cells in the microenvironment did not predict survival.
Details
- Title: Subtitle
- The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
- Creators
- Paul N. Meyer - Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USAKai Fu - Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USATimothy Greiner - Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USALynette Smith - Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE 68198 USAJan Delabie - University of OsloRandy Gascoyne - British Columbia Canc Agcy, Dept Pathol, Vancouver, BC V5Z 4E6, CanadaGerman Ott - Robert Bosch (Germany)Andreas Rosenwald - University of WürzburgRita Braziel - University of PortlandElias Campo - Pi (United Kingdom)Julie Vose - Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USAGeorg Lenz - Univ Med Berlin, Mol Canc Res Ctr, Berlin, GermanyLouis Staudt - NCI, Dept Pathol, Div Canc Treatment & Diag, Ctr Canc Res, Bethesda, MD 20892 USAWing Chan - Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USADennis D. Weisenburger - Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA
- Resource Type
- Journal article
- Publication Details
- American journal of clinical pathology, Vol.135(1), pp.54-61
- DOI
- 10.1309/AJCPJX4BJV9NLQHY
- PMID
- 21173124
- NLM abbreviation
- Am J Clin Pathol
- ISSN
- 0002-9173
- eISSN
- 1943-7722
- Publisher
- Oxford Univ Press
- Number of pages
- 8
- Language
- English
- Date published
- 01/01/2011
- Academic Unit
- Pathology
- Record Identifier
- 9984823122002771
Metrics
3 Record Views